Skip to content

ElectroPhySiological Characterization Of the Arrhythmia Substrate for Sudden Cardiac Death PrEdiction

ElectroPhySiological Characterization Of the Arrhythmia Substrate for Sudden Cardiac Death PrEdiction

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07020702
Acronym
EP-SCOPE
Enrollment
210
Registered
2025-06-13
Start date
2023-06-12
Completion date
2030-09-12
Last updated
2025-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathies, Left Ventricular Ejection Fraction Less Then or Equal to 50percent, Ventricular Arrhythmia

Keywords

cardiomyopathies, sudden death, Myocardial Infarction

Brief summary

EP-SCOPE is a prospective, multicentric, non-randomized pilot study that aims to estimate the risk of life-threatening ventricular arrhythmia through use of advanced electrophysiological studies in patients with ischemic or non-ischemic cardiomyopathy with left ventricular ejection fraction (LVEF) \<50% and risk factors of ventricular arrhythmia, otherwise not considered for implantation of an implantable cardioverter defibrillator (ICD). The objective is to assess the effectiveness of a risk stratification strategy based on detailed electrophysiological exploration of the left ventricle and programmed ventricular stimulation.

Detailed description

Responsible for 10% of deaths in the general population, sudden cardiac death is mostly caused by malignant ventricular arrhythmias (80%). These arrhythmias mainly occur in cardiomyopathies (75-90%). Currently, the prevention of sudden death is based on risk stratification according to the evaluation of myocardial contractility with indications for prophylactic ICD implantation reserved for LVEF ≤ 35%. This predictor is notoriously insufficient for several main reasons: 1) While ICDs are indicated in patients with LVEF ≤35%, only a minority (2 -5% per year) will suffer from arrhythmia and therefore benefits from ICD implantation, while all will be subject to potential complications. 2) The majority of sudden death (70-80%) occur in patients with LVEF \>35%; while they have a lower arrhythmia risk (1-2% per year), they constitute a population four times larger, which is not stratified. 3) Finally, the cardiomyopathy population is broad, and include distinct clinical scenarios that are not specifically addressed. While conventional electrophysiological studies only boast a limited number of measurements, the proposed strategy is a detailed electrophysiological characterization of the altered ventricle. Measurements include a detailed mapping of the left ventricle in the basal state and during extrastimuli, and programmed stimulation of the right and left ventricle including the simultaneous recording of the Purkinje system. Follow-up will be performed for 3 years, looking for the occurrence of major arrhythmic events such as: 1) Appropriate therapy (for VT/VF) delivered by an ICD or 2) documented ventricular arrhythmia on ECG, implantable loop recorder or pacemaker or 3) Clinical sudden death.

Interventions

DEVICEImplantation of an ICD

Implantation of an ICD

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient with cardiomyopathy with 35%\<LVEF\<50% and at least one risk factor * Patients with cardiomyopathy with LVEF≤35% and an indication for cardiac resynchronisation

Exclusion criteria

* Patients who are minors or aged 80 or over * Patients with unstable coronary artery disease * Myocardial infarction less than 40 days old * Coronary revascularisation \<90 days * Patients with intracardiac thrombus * Patients with a mechanical heart valve * Patient implanted with an automatic defibrillator * Patient life expectancy \<1 year * Pregnant or breast-feeding women * Anti-arrhythmic drugs other than beta-blockers and amiodarone

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of major rhythmic events60 monthsFollow-up on Occurrence of major rhythmic events

Secondary

MeasureTime frameDescription
Surfaces distributions of abnormal ventricular potentialsDay 1
Spatial distributions of abnormal ventricular potentialsDay 1
Purkinje potentials in induced arrhythmiasDay 1Presence or absence

Countries

France

Contacts

Primary ContactSylvain PLOUX, MD
sylvain.ploux@chu-bordeaux.fr+33(0)5 57 65 64 71
Backup ContactMélissa LABEQUE
melissa.lavevre@chu-bordeaux.fr+33(0)5 57 62 31 32

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026